SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Fidelity Select Sector funds
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dennis who wrote (141)9/14/1997 8:15:00 PM
From: Haolin Ni   of 4916
 
Dennis, AVIR has no future. As a virologist, I know the live attenuated flu vaccine is just wast time and money due to virus antigenic changing continuously. So each live attnuated flu vaccine could only be useful for few years and need to develope new attenuated vaccine virus continuously although the nosal delivery is very good idead. The critical point is that no one in the world could develope save attenuated virus vaccines with same method repeatly. Therefore, each new live vaccine must pass independent clinical trials, which will cost a lot of money and time to do so. No live attenuated flu vaccine would be ready for the epidemic flu. But dead flu virus vaccines are using and developing to be deliveried orally. The same technique could produce save dead virus vaccine easyly.

You need do your own research to investigate the potential future of AVIR but you need to distiguish the drug and vaccine clearly. A drug passed third phase clinical trial could be used for decades.

Good luck!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News